UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 179

Sortiert nach

Recombinant ADAMTS13 normalizes von Willebrand factor‐cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies

Journal of thrombosis and haemostasis, 2011-05, Vol.9 (5), p.936-944

2011

Link zum Volltext

Verfügbarkeit prüfen

Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH‐AH 01/2010 study

Journal of thrombosis and haemostasis, 2016-05, Vol.14 (5), p.940-947

2016

Link zum Volltext

Verfügbarkeit prüfen

High proportion of patients with bleeding of unknown cause in persons with a mild‐to‐moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB)

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-05, Vol.24 (3), p.405-413

2018

Link zum Volltext

Verfügbarkeit prüfen

Consensus statement for cancer patients requiring intensive care support

Annals of hematology, 2018-07, Vol.97 (7), p.1271-1282

2018

Link zum Volltext

Verfügbarkeit prüfen

Treatment of thrombotic microangiopathy with a focus on new treatment options

Hämostaseologie, 2013-05, Vol.33 (2), p.149

Knöbl, P N

2013

Link zum Volltext

Verfügbarkeit prüfen

Thrombopenie auf der Intensivstation: Diagnose, Differenzialdiagnose und Therapie

Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2016-06, Vol.111 (5), p.425-433

Knöbl, P.

2016

Link zum Volltext

Verfügbarkeit prüfen

Thrombocytopenia in the intensive care unit : Diagnosis, differential diagnosis, and treatment

Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2016-06, Vol.111 (5), p.425-433

Knöbl, P

2016

Link zum Volltext

Verfügbarkeit prüfen

The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients

International journal of antimicrobial agents, 2010-12, Vol.36 (6), p.531-536

2010

Link zum Volltext

Verfügbarkeit prüfen

Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura

Journal of thrombosis and haemostasis, 2017-07, Vol.15 (7), p.1448-1452

2017

Link zum Volltext

Verfügbarkeit prüfen

S294: LONG‐TERM SAFETY AND EFFICACY OF CAPLACIZUMAB FOR ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP): THE POST‐HERCULES STUDY

HemaSphere, 2022-06, Vol.6, p.195-196

2022

Link zum Volltext

Verfügbarkeit prüfen

Inverse correlation of free and immune complex‐sequestered anti‐ADAMTS13 antibodies in a patient with acquired thrombotic thrombocytopenic purpura

Journal of thrombosis and haemostasis, 2012-01, Vol.10 (1), p.156-158

2012

Link zum Volltext

Verfügbarkeit prüfen

NET untangled in TMA?

Journal of thrombosis and haemostasis, 2015-05, Vol.13 (5), p.729-731

Knobl, P

2015

Link zum Volltext

Verfügbarkeit prüfen

Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry

Hämostaseologie, 2013, Vol.33 (2), p.138

2013

Link zum Volltext

Verfügbarkeit prüfen

Thrombocytopenia in the intensive care unit : Diagnosis, differential diagnosis, and treatment

Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2016-06, Vol.111 (5), p.425

Knöbl, P

2016

Link zum Volltext

Verfügbarkeit prüfen

Unraveling the immunologic response in thrombotic thrombocytopenic purpura

Journal of thrombosis and haemostasis, 2006-11, Vol.4 (11), p.2352-2354

KNÖBL, P.

2006

Link zum Volltext

Verfügbarkeit prüfen

Fibrin sealant produced by the CryoSeal® FS System: product chemistry, material properties and possible preparation in the autologous preoperative setting

Vox sanguinis, 2004-05, Vol.86 (4), p.257-262

2004

Link zum Volltext

Verfügbarkeit prüfen

Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems

Transfusion (Philadelphia, Pa.), 2000-05, Vol.40 (5), p.543-550

2000

Link zum Volltext

Verfügbarkeit prüfen

Thrombopenie auf der Intensivstation: Diagnose, Differenzialdiagnose und Therapie

Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2016-01, Vol.111 (5), p.425-433

Knöbl, P.

2016

Link zum Volltext

Verfügbarkeit prüfen

Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy

European journal of clinical investigation, 2007-10, Vol.37 (10), p.808-813

2007

Link zum Volltext

Verfügbarkeit prüfen

Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse

Leukemia, 2004-02, Vol.18 (2), p.293-302

2004

Link zum Volltext

Verfügbarkeit prüfen

The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease

Thrombosis and haemostasis, 2012-08, Vol.108 (2), p.284

2012

Link zum Volltext

Verfügbarkeit prüfen

A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura

Thrombosis and haemostasis, 2011-09, Vol.106 (3), p.539

2011

Link zum Volltext

Verfügbarkeit prüfen

A novel flow‐based assay reveals discrepancies in ADAMTS‐13 inhibitor assessment as compared with a conventional clinical static assay

Journal of thrombosis and haemostasis, 2014-09, Vol.12 (9), p.1523-1532

2014

Link zum Volltext

Verfügbarkeit prüfen

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

The New England journal of medicine, 2019-01, Vol.380 (4), p.335-346

2019

Link zum Volltext

Verfügbarkeit prüfen

A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease

Thrombosis and haemostasis, 2010-09, Vol.104 (3), p.563

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 179

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(162)
Mit Volltextzugriff
(140)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(132)
Life Sciences & Biomedicine
(131)
Humans
(121)
Female
(79)
Male
(77)
Hematology
(75)
Middle Aged
(73)
Adult
(72)
Biological And Medical Sciences
(70)
Medical Sciences
(65)
Aged
(46)
Hematologic And Hematopoietic Diseases
(26)
Adolescent
(25)
Cardiovascular System & Cardiology
(25)
Treatment Outcome
(23)
Peripheral Vascular Disease
(22)
Pharmacology. Drug Treatments
(20)
Animals
(17)
Anesthesia. Intensive Care Medicine. Transfusions. Cell Therapy And Gene Therapy
(16)
Aged, 80 And Over
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Recombinant ADAMTS13 normalizes von Willebrand factor‐cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies

Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH‐AH 01/2010 study

High proportion of patients with bleeding of unknown cause in persons with a mild‐to‐moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB)

Consensus statement for cancer patients requiring intensive care support

Treatment of thrombotic microangiopathy with a focus on new treatment options

Thrombopenie auf der Intensivstation: Diagnose, Differenzialdiagnose und Therapie

Thrombocytopenia in the intensive care unit : Diagnosis, differential diagnosis, and treatment

The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients

Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura

S294: LONG‐TERM SAFETY AND EFFICACY OF CAPLACIZUMAB FOR ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP): THE POST‐HERCULES STUDY

Inverse correlation of free and immune complex‐sequestered anti‐ADAMTS13 antibodies in a patient with acquired thrombotic thrombocytopenic purpura

NET untangled in TMA?

Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry

Thrombocytopenia in the intensive care unit : Diagnosis, differential diagnosis, and treatment

Unraveling the immunologic response in thrombotic thrombocytopenic purpura

Fibrin sealant produced by the CryoSeal® FS System: product chemistry, material properties and possible preparation in the autologous preoperative setting

Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems

Thrombopenie auf der Intensivstation: Diagnose, Differenzialdiagnose und Therapie

Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy

Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse

The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease

A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura

A novel flow‐based assay reveals discrepancies in ADAMTS‐13 inhibitor assessment as compared with a conventional clinical static assay

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease

Suchergebnisse filtern